Paradeep Phosphates Limited (BOM:543530)
India · Delayed Price · Currency is INR 224.75
+1.00 (0.45%)
At close: Aug 8, 2025
Inozyme Pharma Cash Flow Statement
Financials in millions INR. Fiscal year is April - March.
Millions INR. Fiscal year is Apr - Mar.
Fiscal Year | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | 2017 - 2021 |
|---|---|---|---|---|---|---|---|
Period Ending | Jun '25 Jun 30, 2025 | Mar '25 Mar 31, 2025 | Mar '24 Mar 31, 2024 | Mar '23 Mar 31, 2023 | Mar '22 Mar 31, 2022 | Mar '21 Mar 31, 2021 | 2017 - 2021 |
Net Income | - | 5,518 | 999.09 | 3,042 | 3,985 | 2,233 | Upgrade |
Depreciation & Amortization | - | 2,518 | 2,102 | 1,743 | 901.69 | 829.97 | Upgrade |
Other Amortization | - | - | 5.17 | 8.88 | 2.88 | 3.31 | Upgrade |
Loss (Gain) From Sale of Assets | - | 157.7 | 243.11 | 151.19 | 128.94 | 68.99 | Upgrade |
Asset Writedown & Restructuring Costs | - | 94.2 | 79.79 | 123.99 | 209.58 | 76.49 | Upgrade |
Loss (Gain) From Sale of Investments | - | -318.8 | -11.16 | -9.34 | -67.4 | -2.74 | Upgrade |
Loss (Gain) on Equity Investments | - | 7.2 | -6.67 | -5.05 | -6.11 | 1.95 | Upgrade |
Stock-Based Compensation | - | 23.7 | - | - | - | - | Upgrade |
Provision & Write-off of Bad Debts | - | 38.9 | 3.38 | 6.87 | 1.02 | - | Upgrade |
Other Operating Activities | - | 3,598 | 2,609 | 1,833 | 1,315 | 1,875 | Upgrade |
Change in Accounts Receivable | - | 1,751 | 9,643 | -24,238 | -1,063 | 9,857 | Upgrade |
Change in Inventory | - | -4,562 | 4,068 | 1,475 | -13,942 | 1,795 | Upgrade |
Change in Accounts Payable | - | 5,464 | -4,124 | -7,443 | 13,281 | 1,569 | Upgrade |
Change in Other Net Operating Assets | - | -431.1 | -1,243 | -455.68 | -5,185 | -3,295 | Upgrade |
Operating Cash Flow | - | 13,860 | 14,368 | -23,767 | -438.78 | 15,011 | Upgrade |
Operating Cash Flow Growth | - | -3.53% | - | - | - | 18.22% | Upgrade |
Capital Expenditures | - | -3,687 | -4,115 | -4,362 | -6,202 | -1,688 | Upgrade |
Sale of Property, Plant & Equipment | - | 2.5 | 3.88 | 3.77 | 3.84 | 1.1 | Upgrade |
Cash Acquisitions | - | - | - | -5,370 | - | - | Upgrade |
Investment in Securities | - | -2,466 | 405.35 | 5,452 | -4,822 | -1,212 | Upgrade |
Other Investing Activities | - | 184.2 | 37.25 | 89.12 | 32.61 | 5.85 | Upgrade |
Investing Cash Flow | - | -5,966 | -3,669 | -4,187 | -10,988 | -2,893 | Upgrade |
Short-Term Debt Issued | - | 129,723 | 184,580 | 144,998 | 56,811 | 62,720 | Upgrade |
Long-Term Debt Issued | - | 4,619 | 4,611 | 4,392 | 5,725 | 687.88 | Upgrade |
Total Debt Issued | - | 134,342 | 189,191 | 149,390 | 62,535 | 63,408 | Upgrade |
Short-Term Debt Repaid | - | -125,241 | -191,980 | -132,140 | -45,586 | -72,483 | Upgrade |
Long-Term Debt Repaid | - | -5,787 | -3,760 | -1,822 | -661.12 | -987.88 | Upgrade |
Total Debt Repaid | - | -131,028 | -195,740 | -133,962 | -46,247 | -73,470 | Upgrade |
Net Debt Issued (Repaid) | - | 3,314 | -6,549 | 15,428 | 16,289 | -10,062 | Upgrade |
Issuance of Common Stock | - | 26.5 | 30.35 | 9,751 | - | - | Upgrade |
Common Dividends Paid | - | -407.4 | -407.37 | - | - | - | Upgrade |
Other Financing Activities | - | -2,997 | -3,296 | -2,173 | -398.88 | -1,181 | Upgrade |
Financing Cash Flow | - | -63.9 | -10,222 | 23,006 | 15,890 | -11,244 | Upgrade |
Net Cash Flow | - | 7,830 | 476.84 | -4,948 | 4,463 | 874.39 | Upgrade |
Free Cash Flow | - | 10,174 | 10,253 | -28,129 | -6,641 | 13,323 | Upgrade |
Free Cash Flow Growth | - | -0.77% | - | - | - | 17.83% | Upgrade |
Free Cash Flow Margin | - | 7.36% | 8.86% | -21.09% | -8.45% | 25.80% | Upgrade |
Free Cash Flow Per Share | - | 12.46 | 12.57 | -36.06 | -11.54 | 23.15 | Upgrade |
Cash Interest Paid | - | 2,997 | 3,296 | 2,173 | 398.88 | 1,181 | Upgrade |
Cash Income Tax Paid | - | 1,423 | 583.63 | 1,374 | 855.22 | 771.27 | Upgrade |
Levered Free Cash Flow | - | 6,713 | 7,806 | -30,955 | -696.29 | 11,985 | Upgrade |
Unlevered Free Cash Flow | - | 8,977 | 9,814 | -29,383 | -311.83 | 12,620 | Upgrade |
Source: S&P Global Market Intelligence. Standard template. Financial Sources.